v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Convertible Senior Notes Due 2022
Convertible Senior Notes 2025
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Convertible Senior Notes Due 2022
Additional Paid-In Capital
Convertible Senior Notes 2025
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2019         41,908,000              
Beginning balance at Dec. 31, 2019 $ 354,944       $ 42 $ 753,978       $ (399,398)   $ 322
Increase (Decrease) in Stockholders' Equity                        
Exercise of stock options (in shares) 1,428,111       1,428,000              
Exercise of stock options $ 45,229       $ 2 45,227            
Vested restricted stock units (in shares)         239,000              
Common stock issued under employee stock (in shares)         62,000              
Common stock issued under employee stock purchase plan 2,546         2,546            
Stock-based compensation 39,920         39,920            
Issuance of common stock upon conversion     $ (33,089) $ 64,619       $ (33,089) $ 64,619      
Other comprehensive loss (Note 13) (4)                     (4)
Net income 145,523                 145,523    
Ending balance (in shares) at Dec. 31, 2020         43,637,000              
Ending balance at Dec. 31, 2020 $ 619,688       $ 44 873,201       (253,875)   318
Increase (Decrease) in Stockholders' Equity                        
Exercise of stock options (in shares) 732,117       732,000              
Exercise of stock options $ 23,834       $ 1 23,833            
Vested restricted stock units (in shares)         310,000              
Common stock issued under employee stock (in shares)         55,000              
Common stock issued under employee stock purchase plan 2,811         2,811            
Stock-based compensation 42,246         42,246            
Other comprehensive loss (Note 13) (151)                     (151)
Net income 41,980                 41,980    
Ending balance (in shares) at Dec. 31, 2021         44,734,000              
Ending balance at Dec. 31, 2021 $ 730,408 $ (49,233)     $ 45 942,091 $ (96,468)     (211,895) $ 47,235 167
Increase (Decrease) in Stockholders' Equity                        
Reclassification of the equity component of convertible senior notes to liabilities upon adoption of Accounting Standards Update 2020-06 (Note 3) Accounting Standards Update 2020-06                      
Exercise of stock options (in shares) 689,464       690,000              
Exercise of stock options $ 24,387       $ 1 24,386            
Vested restricted stock units (in shares)         331,000              
Common stock issued under employee stock (in shares)         71,000              
Common stock issued under employee stock purchase plan 2,954         2,954            
Stock-based compensation 48,092         48,092            
Issuance of common stock upon conversion (in shares)         102,000              
Issuance of common stock upon conversion     $ 3,040         $ 3,040        
Other comprehensive loss (Note 13) (547)                     (547)
Net income 15,909                 15,909    
Ending balance (in shares) at Dec. 31, 2022         45,928,000              
Ending balance at Dec. 31, 2022 $ 775,010       $ 46 $ 924,095       $ (148,751)   $ (380)